DS-1211b ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 166 | Pseudoxanthoma elasticum | 1 |
166. Pseudoxanthoma elasticum
Clinical trials : 16 / Drugs : 27 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 28
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05569252 (ClinicalTrials.gov) | October 20, 2022 | 4/10/2022 | A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum | A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals With PseudoXanthoma Elasticum | Pseudoxanthoma Elasticum | Drug: DS-1211b;Other: Placebo | Daiichi Sankyo, Inc. | PXE International | Recruiting | 18 Years | 75 Years | All | 64 | Phase 2 | United States;Netherlands |